BPMC News and Press, Blueprint Medicines Corporation From 11/03/22

Blueprint Medicines to Present New Data Reinforcing Clinical Leadership in Systemic Mastocytosis at 2022 ASH Annual Meeting PR Newswire CAMBRIDGE, Mass. , Nov. 3, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the acce...

Oppenheimer downgraded Blueprint Medicines Corporation ( NASDAQ: BPMC ) to Perform from Outperform at Oppenheimer on Wednesday, noting challenges in the rollout of the biotech's cancer therapy Ayvakit. In January 2020, the FDA approved Ayvakit for certain patients with met...

Blueprint Medicines press release ( NASDAQ: BPMC ): Q3 GAAP EPS of -$2.23 beats by $0.28 . Revenue of $65.97M (+172.7% Y/Y) beats by $22.09M . GUIDANCE: Blueprint Medicines anticipates it will achieve the high end of previously provided revenue guidance for ful...

Blueprint Medicines Outlines 2027 Blueprint to Achieve Precision Medicine at Scale and Reports Third Quarter 2022 Financial Results at Investor Day 2022 PR Newswire -- On track to submit supplemental new drug application for AYVAKIT® (avapritinib) in non-advanced ...

Blueprint Medicines to Host Investor Day and Announce Third Quarter 2022 Financial Results on November 1, 2022 PR Newswire CAMBRIDGE, Mass. , Oct. 19, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused...

Summary Shares have fallen by around 80% over the past year. EGFR/HER2 exon 20 and PRC2 inhibitors offer potentially differentiated shots on goal with early data sets expected 1H 2023. Depth and experience of leadership team is a green flag (ex-Ignyta, Medivation, Genentech). ...

Summary Blueprint has a few recently approved therapies, and has recently sold royalties for over $1 billion. While this limits revenue potential now, the profits can be leveraged back into advancing the pipeline. Blueprint can now be assessed like a pre-commercial biotech wit...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass. , Sept. 6, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined ca...

CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis PR Newswire -- Patients across the spectrum of disease reported substantial symptom burden, as well as scores of physical functioning and mental health that are wors...

Gainers: Blue Water Vaccines ( BWV ) +57% . Eargo ( EAR ) +49% . Cassava Sciences ( SAVA ) +29% . MiNK Therapeutics ( INKT ) +24% . Cogent Biosciences ( COGT ) +16% . Losers: Blueprint Medicines ( BPMC ) -22% ....